Resources

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, today announced a further strengthening of its senior leadership with Ian Coyne joining the Managing Partners group. In addition to this strategic leadership expansion, the firm further refined the structure of its Senior Leadership team, with Joe Coulter assuming a new role as Chief Business Officer (CBO) and Charlotte James being promoted to Chief Operating Officer (COO).

Relation today announced a further $26 million investment from existing investors NVentures (NVIDIA’s venture capital arm) and leading deeptech investors DCVC and Magnetic Ventures.

Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has established a consortium to demonstrate how safety tests that detect potentially dangerous undifferentiated residual cells, which can affect product purity, could be applied to a range of a cell therapies.

Scancell Holdings, the developer of active immunotherapies to treat cancer, announces updated positive data from the SCOPE Phase 2 trial of iSCIB1+ in combination with ipilimumab and nivolumab, current standard of care (SoC).

Relation Therapeutics has announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases.

Four projects aimed at identifying the most promising repurposed drug candidates to treat motor neuron disease (MND) have been launched by the self-funded medical research organisation, LifeArc.

Cellular Origins, a TTP company that enables the manufacturing of cell therapies at scale, has completed a $40 million (EUR 34.3 million) over-subscribed Series A round.

Oxford Nanopore Technologies has appointed Francis Van Parys as Chief Executive Officer (CEO). Francis will join the Company and the Board as an Executive Director on 2 March 2026.

Poolbeg Pharma will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme which will facilitate wider research into cancer immunotherapy-induced CRS and the safer delivery of these treatments.

BIA thought leadership takes centre stage with two key reports published: last week saw the release of 'From innovation to impact: unlocking patient access to innovative rare disease medicines', and today 'UK cell and gene therapy: driving efficiencies and innovation' celebrates real-world UK success.

Meet the newly elected BIA Board members bringing fresh expertise to shape the future of life sciences.

Enedra Therapeutics appoints Adrian Ibrahim, PhD, MBA, as its new Chief Executive Officer. Dr Ibrahim will also join the Company’s Board of Directors.

Our latest report demonstrates the real-world success and scalable manufacturing available in the UK’s globally competitive ecosystem.

Just one month after launch, five early-stage science companies have moved into the Leap incubator lab space at ARC West London. The first cohort of innovators joining Leap includes: Solveteq, Reseda Life Sciences, Tachmed, IgEDAPT, and Sea2Carbon.

In this blog, Ethan Almond, Content & Communications Executive at BIA, explores the influence of the BIA’s bioProcessUK conference. The 22nd edition highlighted the UK’s leadership in bioprocessing.

The BioIndustry Association (BIA) released From Innovation to Impact: Unlocking Patient Access to Innovative Rare Disease Medicines, calling for new pathway to give UK patients access to innovative rare disease medicines.